Original Article

Two Chinese nephronophthisis pedigrees harbored a compound heterozygous deletion with a point mutation in \textit{NPHP1}

Huamu Chen\textsuperscript{1,4*}, Hongrong Lin\textsuperscript{1*}, Zhihui Yue\textsuperscript{1}, Haiyan Wang\textsuperscript{2}, Junhui Yang\textsuperscript{3}, Liangzhong Sun\textsuperscript{1,4}

\textsuperscript{1}Department of Pediatrics, Children’s Kidney Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; \textsuperscript{2}Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, P. R. China; \textsuperscript{3}Department of Technical Services, Beijing Mygenostics Co., LTD, Beijing, P. R. China; \textsuperscript{4}Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, P. R. China. *Equal contributors.

Received July 10, 2019; Accepted August 4, 2019; Epub August 15, 2019; Published August 30, 2019

Abstract: \textit{NPHP1} is the most prevalent genetic factor in the development of juvenile nephronophthisis (NPHP). In our previous study, \textit{NPHP1} homozygous point mutations were detected by Sanger sequencing in three cases from two nonconsanguineous pedigrees. However, mutant sites were detected in only one parent from each respective pedigree. To investigate whether other disease-causing mutations were present, targeted exome sequencing (TES) of 63 ciliopathy genes was performed in the probands of the two pedigrees. In addition to the previously detected point mutations, a complete heterozygous deletion of \textit{NPHP1} (1-20 exons) in the other allele was found in each of the three patients. The deletions were inherited from one parent of each pedigree. These is the first report of Chinese NPHP patients harboring a complete heterozygous deletion of \textit{NPHP1} in one allele and a point mutation in the other one. The study demonstrated that TES is helpful in identifying complicated mutations in patients with NPHP.

Keywords: Nephronophthisis, \textit{NPHP1}, heterozygous deletion, targeted exome sequencing

Introduction

Nephronophthisis (NPHP) is an autosomal recessive hereditary cystic kidney disease and is the main genetic factor leading to the development of end-stage renal disease (ESRD) during childhood [1-3]. To date, more than 20 causative genes have been identified, including \textit{NPHP1–NPHP20} [4-6]. \textit{NPHP1} is the most common pathogenic variant of NPHP [2]. Using polymerase chain reaction (PCR) amplification of satellite markers and Sanger sequencing, we previously identified seven patients with \textit{NPHP1} mutations among 27 Chinese juvenile NPHP cases [7]. Three patients from two nonconsanguineous pedigrees were indicated harboring homozygous point mutations by Sanger sequencing. However, a heterozygous mutation at the same site was detected in only one parent in each pedigree. The sources of the observed homozygous status in these patients were not completely clarified. In the present study, we applied targeted exome sequencing (TES) to investigate whether other disease-causing mutations were harbored in these two pedigrees that were presumed to have \textit{NPHP1} homozygous point mutations.

Materials and methods

The study, in accordance with the Declaration of Helsinki, was approved by the ethics committee of the First Affiliated Hospital, Sun Yat-sen University. Written informed consent was obtained from all subjects or their parents. Blood samples and clinical data were collected from the two NPHP pedigrees. DNA was extracted from peripheral blood using a QiAamp DNA Blood Mini Kit (QiAGEN, Germany).

Targeted exome sequencing (TES) was carried out in the two probands (patient F1-II2 and
Patient F2-II1, the older brother of patient F1-II2, was born at full gestational age without asphyxia. Amblyopia was observed at the age of three. Polydipsia, weight loss, and fatigue were observed at the age of 12. He did not visit a doctor until he was 13 years and 7 months old, at which point he was found to have renal impairment (Scr 166.8 µmol/L; estimated glomerular filtration rate (eGFR) 36.4 mL/min/1.73 m²) and anemia (hemoglobin 98-103 g/L). Urinalysis was normal except for decreased urinary gravity (1.000). The patient exhibited normal intelligence, was 147 cm (<-3 SDS) tall, and weighed 31.5 kg (<-3 SDS). His blood pressure was 110-120/65-70 mmHg. Ultrasonography showed that his right kidney was normal in size (92 mm × 33 mm), while his left kidney was dysplastic (32 mm × 38 mm). Increased echogenicity and a loss of corticomedullary differentiation were observed in both kidneys. No cysts were found in either kidney, and his liver was normal based on what was revealed by ultrasonography. He progressed to ESRD at the age of 16 years and 7 months, with an Scr level of 1400 µmol/L.

Pedigree 2 (F2): Patient F2-II1 (the proband) was a male showing normal vision and intelligence. He had anorexia, fatigue, and growth retardation at the age of nine. Laboratory data revealed renal impairment (Scr 240 µmol/L) and anemia (hemoglobin 60 g/L). His blood pressure was 150/100 mmHg. One year later, he progressed to ESRD (Scr 900 µmol/L). The patient was 125 cm (-3.1 SDS) tall and weighed 24 kg (-2.2 SDS) at 11 years and 9 months. Urinalysis showed proteinuria 1+. Ultrasonography of the kidneys revealed reduced size (left: 66 mm × 29 mm, right: 60 mm × 27 mm), hyperechogenicity, and loss of corticomedullary differentiation. A single cyst (5 mm × 5 mm) was found in his right kidney. His liver function was normal.

TES results and bioinformatic analysis

TES was performed in the probands of the two pedigrees (patient F1-II2 and patient F2-II1). The percentage of the target region captured with more than 10 × was 92.38% in the proband of pedigree 1 and 97.3% in the proband of pedigree 2. Apart from the point mutations consistent with our previous Sanger sequencing results (Figure 1), an entire heterozygous dele-
Nephronophthisis patients with *NPHP1* heterozygous deletion
Nephronophthisis patients with \textit{NPHP1} heterozygous deletion

\textbf{Figure 1.} \textit{NPHP1} complete heterozygous deletion identified in two pedigrees and point mutations verified by Sanger sequencing. A-C (pedigree 1): A: The filled square and circle denote the patients in the pedigree. B: A complete heterozygous deletion of \textit{NPHP1} was detected in F1-II2 by TES (red rectangle). C: A complete heterozygous deletion of \textit{NPHP1} in patients F1-II1 and F1-II2 and their father (F1-I1) was confirmed by Q-PCR (red rectangle); the mother was spared. D-F (pedigree 2): A complete heterozygous deletion of \textit{NPHP1} in patient F2-II1 and his mother (F2-I2) detected by TES, and was confirmed by quantitative polymerase chain reaction. (AE1-23: Exon 1-23 of \textit{ALMS1}, E1-20: Exon 1-20 of \textit{NPHP1}, TE1-29: Exon 1-29 of \textit{TTC21B}. C1-C4 are the control samples). G-N: Point mutations verified by Sanger sequencing in two pedigrees.
Nephronophthisis patients with NPHP1 heterozygous deletion

The complete deletion in NPHP1 identified in both pedigrees would lead to the loss of expression of its encoded protein, nephrocystin 1. The nonsense mutation (c.1756C>T, p.R586X) of NPHP1 in pedigree 1 and the frameshift mutation (c.1298delA, p.K433Sfs*55) in pedigree 2 were both predicted to create a premature stop codon and cause truncation of nephrocystin 1.

The original data from TES are available in the NCBI Sequence Read Archive (SRA) (accession number: SRP100717).

Discussion

NPHP1 was the first NPHP gene identified [8], and its mutations have been identified in 19.7%-29.4% of all NPHP cases [2, 8]. Most patients with NPHP1 mutations manifest with juvenile NPHP [9, 10]. Clinically, homozygous deletions are the most frequent type of NPHP1 mutation and are observed in approximately 85% of NPHP1 mutant cases [11]. Compound point mutations and compound heterozygous deletions with point mutations are not common [12]. The compound heterozygous deletion with a point mutation in NPHP1 identified in two pedigrees in the present study was determined to be disease-causing based on bioinformatics analysis. Both of the point mutations identified in the two pedigrees were truncation mutations that had been reported previously in other patients with NPHP [2, 13]. Compound heterozygous deletion with a point mutation in NPHP1 alleles has not been reported before in Chinese NPHP patients.

Non-quantitative PCR and Sanger sequencing cannot distinguish compound heterozygous deletion in one allele with a point mutation in the other from cases with homozygous point mutations [14]. When the source of the point mutation cannot be identified in either parent, other causative mutations including heterozygous fragment deletions and CNVs of the pathogenic gene or mutations in other causative genes should be considered. In the present study, 62 additional candidate ciliopathy genes were screened simultaneously by TES and were excluded as causative genes in these two pedigrees.

Large heterozygous NPHP1 deletions could also be detected by other methods, such as in situ hybridization and single-strand conformation polymorphism analysis [13, 15]. However, it is difficult to ascertain the location and the extent of the deleted fragment with these methods. Quantitative multiplex PCR of short fluorescent fragments was also recently applied for the detection of NPHP1 heterozygous deletion [16].

In conclusion, we identified a complete heterozygous deletion with a point mutation in NPHP1 on the second allele in two Chinese NPHP pedigrees. In patients with a homozygous mutation indicated by direct sequencing for whom the source of each copy of the mutation is not confirmed, further exploration of the causative mutations is warranted. The results of this study demonstrated that TES is helpful in identifying complicated mutations in patients with NPHP.

Acknowledgements

The study was supported by the National Natural Science Foundation of China (Grant No. 81670610 and No. 81470913). We are grateful to all participants for their support in this study.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Liangzhong Sun, Department of Pediatrics, Children’s Kidney Disease Center, The First Affiliated Hospital, Sun Yat-sen University, 58, Zhongshan Road 2, Guangzhou, Guangdong, P. R. China; Department of Pediatrics, Nanfang Hospital, Southern Medical University, 1838, North Guangzhou Avenue, Guangzhou, Guangdong Province, P. R. China. Tel: +86 1331620-2736; E-mail: sunlzh2018@smu.edu.cn

References


57


